M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 10, Issue 1, Pages 1862520
Publisher
Informa UK Limited
Online
2020-12-31
DOI
10.1080/2162402x.2020.1862520
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
- (2020) Juliette Palle et al. DRUGS
- Current status of immune checkpoint inhibitors for gastric cancer
- (2020) Koji Kono et al. Gastric Cancer
- Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypes
- (2020) Benjamin R Challoner et al. JNCI-Journal of the National Cancer Institute
- Current Molecular Targeted Agents for Advanced Gastric Cancer
- (2020) Shanshan Nie et al. OncoTargets and Therapy
- Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients
- (2020) Hongyu Zhang et al. ANNALS OF SURGERY
- The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
- (2020) V. Gambardella et al. CANCER TREATMENT REVIEWS
- An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
- (2020) Shogo Kumagai et al. IMMUNITY
- CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner
- (2020) Marine M. Leblond et al. Cancer Immunology Research
- Functional genomic landscape of cancer-intrinsic evasion of killing by T cells
- (2020) Keith A. Lawson et al. NATURE
- Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
- (2019) Saori Mishima et al. Journal for ImmunoTherapy of Cancer
- Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
- (2019) Cong Chen et al. OncoImmunology
- PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
- (2019) Rui Zhao et al. CELL PROLIFERATION
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Targeting Tumor-Associated Macrophages in Cancer
- (2019) Paulina Pathria et al. TRENDS IN IMMUNOLOGY
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Diversity, Mechanisms, and Significance of Macrophage Plasticity
- (2019) Massimo Locati et al. Annual Review of Pathology-Mechanisms of Disease
- Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer
- (2019) Kohei Yamashita et al. Gastric Cancer
- Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry
- (2019) Yu-Kuan Huang et al. Nature Communications
- CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
- (2018) Chenlu Zhang et al. BMC CANCER
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- The Immune Revolution: A Case for Priming, Not Checkpoint
- (2018) Robert H. Vonderheide CANCER CELL
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- A proteomic landscape of diffuse-type gastric cancer
- (2018) Sai Ge et al. Nature Communications
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- THE PROTEASE-DEPENDENT MESENCHYMAL MIGRATION OF TUMOR-ASSOCIATED MACROPHAGES AS A TARGET IN CANCER IMMUNOTHERAPY
- (2018) Philippe Gui et al. Cancer Immunology Research
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
- (2018) N Boku et al. ANNALS OF ONCOLOGY
- Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
- (2018) Toshihiko Doi et al. Gastric Cancer
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma
- (2017) Kazuto Harada et al. Gastric Cancer
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein
- (2017) Yulei Chen et al. Journal of Hematology & Oncology
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
- (2017) Manisha Singh et al. Nature Communications
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
- (2016) Elizabeth D Thompson et al. GUT
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
- (2015) M. E. Mikucki et al. Nature Communications
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search